CDXC: ChromaDex Corporation Stock

by  •  • Comments Off on CDXC: ChromaDex Corporation Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 613.99
Enterprise Value ($M) 569.48
Book Value ($M) 46.09
Book Value / Share 0.59
Price / Book 13.32
NCAV ($M) 41.92
NCAV / Share 0.54
Price / NCAV 14.65

Profitability (mra)
Return on Invested Capital (ROIC) 0.18
Return on Assets (ROA) 0.16
Return on Equity (ROE) 0.30

Liquidity (mrq)
Quick Ratio 3.06
Current Ratio 3.57

Balance Sheet (mrq) ($M)
Current Assets 64.10
Assets 68.28
Liabilities 22.18
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 99.60
Operating Income 7.73
Net Income 8.55
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 12.11
Cash from Investing -0.14
Cash from Financing 5.37

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
08-21 13D/A Prime Tech Global Ltd 0.00
08-21 13D/A Pioneer Step Holdings Ltd 25.41 144.68

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-04 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number: 001-37752
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number: 001-3775

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-11 136,452 1,120,986 12.17
2025-03-10 173,146 1,031,765 16.78
2025-03-07 143,899 1,007,741 14.28
2025-03-06 334,874 2,188,430 15.30

(click for more detail)

Similar Companies
CASI – CASI Pharmaceuticals, Inc. CDIO – Cardio Diagnostics Holdings, Inc.
CDTX – Cidara Therapeutics, Inc. CELU – Celularity Inc.
CELZ – Creative Medical Technology Holdings, Inc.


Financial data and stock pages provided by
Fintel.io